Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aviron finds deep Korean pockets

As companies search for sources of financing that allow them to do more than merely survive, kudos go to those that can come up with untapped, deep pockets partners. Aviron has done just that, announcing a collaboration with Sang-A, a Korean pharmaceutical company and member of the Hanbo Group conglomerate.

Sang-A will make an equity investment for 10 percent to 25 percent of Aviron, and the Korean company will participate in future financings.

Read the full 727 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE